Rein Therapeutics (NASDAQ:RNTX) Releases Quarterly Earnings Results

Rein Therapeutics (NASDAQ:RNTX) announced its quarterly earnings data on Monday. The company reported ($0.26) earnings per share for the quarter, Zacks reports.

Rein Therapeutics Trading Down 3.5 %

RNTX opened at $1.64 on Tuesday. The firm has a market cap of $35.53 million, a P/E ratio of -0.53 and a beta of 2.12. The firm has a 50 day moving average of $2.04. Rein Therapeutics has a 1-year low of $1.50 and a 1-year high of $7.42.

About Rein Therapeutics

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.